OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Campbell on Radical Nephrectomy in RCC

August 22nd 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the role of radical nephrectomy according to the guidelines for patients with renal cell carcinoma (RCC).

Dr. Badani Discusses the Adoption of Robotic Kidney Surgery

August 21st 2017

Ketan K. Badani, MD, professor of urology at Mount Sinai Hospital, discusses the adoption of robotic surgery in kidney cancer.

Dr. Choyke Discusses the Challenges With MRI in Prostate Cancer

August 21st 2017

Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses the challenges with MRI in prostate cancer.

Dr. Nastoupil on Questions Surrounding TGR1202 in Patients With CLL

August 21st 2017

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the questions researchers are currently facing with TGR1202 in patients with chronic lymphocytic leukemia (CLL).

Dr. Choueiri on the Biology of the CABOSUN Trial for RCC

August 21st 2017

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the findings of the CABOSUN trial for patients with metastatic renal cell carcinoma (mRCC).

Dr. Stephenson on the Development of Biomarkers for Prostate Cancer

August 21st 2017

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the development of biomarkers for patients with prostate cancer.

Dr. Hamlin on Next Steps With Ibrutinib/Buparlisib in MCL, FL, and DLBCL

August 21st 2017

Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses the next steps following a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Dr. Gradishar on Selecting Agents for HER2+ Breast Cancer

August 18th 2017

William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine (Hematology and Oncology), Northwestern University Feinberg School of Medicine, discusses selecting agents for the treatment of patients with HER2-positive breast cancer.

Dr. Siegel on the Da Vinci Robotic Assisted Surgery Technique in Head and Neck Cancer

August 18th 2017

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses the da Vinci robotic-assisted surgery technique in head and neck cancer.

Dr. Higano on Combinations With Radium-223 for Prostate Cancer

August 18th 2017

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses risks associated with combining radium-223 dichloride (Xofigo) for patients with prostate cancer.

Dr. Albiges on Next Steps for Immunotherapy in RCC

August 18th 2017

Laurence Albiges, MD, ‎medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses the next steps for immunotherapy for patients with renal cell carcinoma (RCC).

Dr. Roboz on Advancements on the Horizon in AML

August 18th 2017

Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses advancements emerging on the horizon in acute myeloid leukemia (AML).

Dr. Martin on Potential of Immunotherapy in MCL Landscape

August 18th 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of modern immunotherapies in the landscape of mantle cell lymphoma (MCL).

Dr. Modest Discusses the German AIO KRK0110 Study in CRC

August 18th 2017

Dominik P. Modest, MD, University of Munich, discusses the German AIO KRK0110 study in metastatic colorectal cancer.

Dr. Feldman on Remaining Challenges With Biomarkers in Prostate Cancer

August 18th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.

Dr. Black on Selecting Immunotherapy Agents in Bladder Cancer

August 18th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses selecting immunotherapy agents in bladder cancer.

Dr. Sartor on the Science of Sipuleucel-T for Prostate Cancer

August 18th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the science behind the results of a study investigating sipuleucel-T (Provenge) for patients with castration-resistant prostate cancer (CRPC).

Dr. Bauml on the Unmet Need in Head and Neck Cancer

August 18th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses an unmet need for patients with head and neck cancer.

Dr. Willmott on FDA Approval of Maintenance Olaparib in Ovarian Cancer

August 17th 2017

Lyndsay J. Willmott, MD, a gynecologic oncologist with Arizona Oncology, discusses the FDA approval of olaparib (Lynparza) in the maintenance setting for relapsed patients with platinum-sensitive ovarian cancer.

Dr. Al-Kali on FDA Approval of Inotuzumab Ozagamicin in ALL

August 17th 2017

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of inotuzumab ozagamicin for the treatment of patients with acute lymphoblastic leukemia (ALL).